| 摘要 |
PCT No. PCT/US96/15854 Sec. 371 Date Apr. 7, 1998 Sec. 102(e) Date Apr. 7, 1998 PCT Filed Oct. 2, 1996 PCT Pub. No. WO97/16184 PCT Pub. Date May 9, 1997The present invention is a combination of an ACAT inhibitor, for example, sulfamic acid, [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl) phenyl ester, and an HMG-CoA-reductase inhibitor, for example, atorvastatin, effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoportein profile The combination is useful in the treatment of patents with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.
|
